Menu
Search
|

Menu

Close
X

Selecta Biosciences Inc SELB.OQ (NASDAQ Stock Exchange Global Market)

1.63 USD
-0.01 (-0.61%)
As of Jul 23
Previous Close 1.64
Open 1.65
Volume 26,896
3m Avg Volume 132,234
Today’s High 1.66
Today’s Low 1.60
52 Week High 16.47
52 Week Low 1.41
Shares Outstanding (mil) 44.79
Market Capitalization (mil) 73.45
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.40 Mean rating from 5 analysts

KEY STATS

Revenue (mm, USD)
FY19
0
FY18
1
FY17
0
FY16
8
EPS (USD)
FY19
-0.314
FY18
-2.919
FY17
-3.209
FY16
-5.103
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
34.39
Price to Sales (TTM)
vs sector
80.45
8.16
Price to Book (MRQ)
vs sector
4.96
4.43
Price to Cash Flow (TTM)
vs sector
--
24.27
Total Debt to Equity (MRQ)
vs sector
144.85
17.60
LT Debt to Equity (MRQ)
vs sector
0.00
12.56
Return on Investment (TTM)
vs sector
-114.39
12.67
Return on Equity (TTM)
vs sector
-218.16
17.18

EXECUTIVE LEADERSHIP

Omid Farokhzad
Chairman of the Board, Since 2017
Salary: --
Bonus: --
Carsten Brunn
President, Chief Executive Officer, Director, Since 2018
Salary: $42,308.00
Bonus: $97,917.00
Lloyd Johnston
Chief Operating Officer, Senior Vice President - Research & development, Since
Salary: $345,000.00
Bonus: --
Takashi Kishimoto
Chief Scientific Officer, Since
Salary: --
Bonus: --
Elona Kogan
General Counsel, Secretary, Since 2019
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

480 Arsenal Way
WATERTOWN   MA   02472-2891

Phone: +1617.9231400

Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company using its synthetic vaccine particle (SVP) technology to discover and develop targeted therapies that are designed to modulate the immune system to treat rare and serious diseases. The Company is engaged in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its product candidates are in various stages of clinical and preclinical development. Its SVP technology encapsulates an immunomodulator in biodegradable nanoparticles to induce antigen-specific immune tolerance to mitigate the formation of anti-drug antibodies (ADAs) in response to life-sustaining biologic drugs. The Company's lead product candidate, SEL-212, is a combination of a therapeutic enzyme and its SVP technology designed to be the biologic treatment for gout.

SPONSORED STORIES